Clinical Trial Update: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) [Phase 2]

View source ↗

Summary

Phase 2 trial update for ceritinib in tumors with ALK or ROS1 aberrations; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancers of Unknown Primary
• Tumors with Aberrations in Alk or Ros1

Drugs mentioned

• Ceritinib (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tumors With Aberrations in ALK or ROS1 | Phase 2 | Status: TERMINATED | Results posted: 2021-04-08